India is increasingly witnessing the medicalisation of obesity, where excess body weight is being treated primarily through pharmaceutical interventions rather than addressing its structural and lifestyle determinants.
The growing use of drugs such as Semaglutide, along with practices like BMI-linked job fitness criteria by Air India, reflects a shift toward defining health through measurable indicators and drug-based solutions rather than holistic well-being.
Obesity in India: A Growing Public Health Crisis
Rising Burden and Metabolic Risks
Obesity in India has emerged as a silent epidemic, with nearly one-fourth of the population being overweight or obese. This rise is closely linked with increasing prevalence of metabolic disorders such as diabetes and hypertension, affecting a significant proportion of adults.
The burden is no longer restricted to urban elites but is spreading across socio-economic groups, including children, making it a long-term demographic and health concern.
The “Thin-Fat” Phenotype and Indian Vulnerability
A distinctive feature of obesity in India is the “thin-fat phenotype,” wherein individuals may appear lean but carry high levels of visceral fat.
This genetic predisposition makes Indians more susceptible to metabolic diseases at lower BMI levels, complicating diagnosis and management and making conventional obesity metrics less effective.
Lifestyle and Socio-Cultural Transition
The rise in obesity is also deeply rooted in changing lifestyles. Rapid urbanisation, sedentary work patterns, reduced physical activity, shrinking open spaces, and chronic stress have collectively altered health behaviours.
What was once culturally associated with affluence has now transformed into a marker of declining metabolic health.
Also read:
Industrial Accidents in India: Bridging the Gap Between Growth and Safety
Understanding Medicalisation of Obesity
From Lifestyle Issue to Medical Condition
Medicalisation refers to the process by which conditions rooted in social and behavioural factors are redefined as medical problems requiring clinical treatment.
In the case of obesity, this shift has led to an increasing dependence on pharmacological solutions instead of addressing core issues such as unhealthy diets and physical inactivity.
Role of GLP-1 Based Drugs
Modern anti-obesity drugs function through the GLP-1 pathway, which suppresses appetite and slows gastric emptying.
While these mechanisms help in short-term weight reduction, they do not fundamentally alter the lifestyle or environmental triggers of obesity, thereby limiting their long-term effectiveness.
Pharmaceutical Expansion and the “Cascading Logic”
Market Growth and Drug Accessibility
The anti-obesity drug market in India is expanding rapidly, especially with the availability of cheaper versions of Semaglutide following patent expiries.
Increased accessibility has led to wider usage, often without adequate medical supervision or awareness of long-term consequences.
Surrogate Advertising and Demand Creation
Despite restrictions on direct advertising, pharmaceutical companies rely on indirect promotional strategies such as influencer marketing and awareness campaigns.
These approaches shape public perception by portraying weight-loss drugs as convenient and effective solutions, thereby normalising their use.
The Sarcopenia Cycle and Drug Dependency
A critical concern is the unintended consequence of muscle loss, or sarcopenia, associated with rapid drug-induced weight loss.
Instead of addressing this through lifestyle interventions like strength training, there is a growing trend of developing additional drugs to manage these side effects.
This creates a cascading cycle, where one treatment leads to another, fostering long-term pharmaceutical dependency.
Role of the Food Industry: Structural Drivers of Obesity
Expansion of Ultra-Processed Foods
The increasing consumption of ultra-processed foods, rich in sugar, salt, and unhealthy fats, has significantly contributed to the obesity crisis.
Their affordability, convenience, and aggressive marketing have made them a staple in modern diets, particularly in urban areas.
Regulatory Challenges and Policy Delays
Efforts to regulate unhealthy food consumption, such as Front-of-Package Labelling, have faced delays due to industry resistance.
This highlights the tension between public health objectives and commercial interests, often resulting in weakened policy implementation.
The Public Health Paradox
A paradoxical situation emerges where one sector promotes unhealthy consumption patterns while another offers medical remedies for the resulting conditions.
This creates a system that is economically profitable but misaligned with long-term public health goals.
Ethical and Governance Concerns
Commercial Influence on Medical Practice
The shrinking time gap between drug approval and their inclusion in clinical guidelines raises concerns about the influence of pharmaceutical companies on medical decision-making. This may compromise evidence-based practice and patient safety.
BMI-Based Institutional Pressures
The use of BMI as a strict criterion in employment or performance evaluation can inadvertently push individuals toward rapid and potentially unsafe weight-loss methods, including excessive reliance on drugs.
Regulatory Lag and Weak Oversight
Government regulation often lags behind evolving marketing strategies, allowing misleading narratives to shape public perception before corrective measures are implemented.
Way Forward
Re-centering Lifestyle-Based Interventions
Addressing obesity requires prioritising preventive strategies such as balanced nutrition, regular physical activity, adequate sleep, and stress management.
These interventions tackle the root causes rather than merely alleviating symptoms.
Ensuring Transparency and Ethical Practice
There is a need for clear communication regarding the long-term risks associated with anti-obesity drugs, including muscle loss. The medical community must emphasise sustainable health outcomes over quick fixes.
Strengthening Regulatory Frameworks
Effective implementation of policies such as Front-of-Package warning labels and stricter regulation of unhealthy food marketing is essential to curb the drivers of obesity.
Conclusion
The rise of drugs like Semaglutide highlights the growing medicalisation of obesity in India. While such medications can play a supportive role, they should not replace efforts to address the structural and behavioural determinants of health.
A sustainable response to obesity lies in shifting the focus from pharmaceutical dependence to holistic well-being and preventive public health strategies.
Admin